Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS

Persistent Unmet Need Fuels Antiviral Drug Development for Bloodborne Pathogens

Regular Price: USD 1,500

Special Price USD 1,275

15% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,275

PAY BY INVOICE

Be the first to review this product

This research service focuses on antiviral/antiretroviral therapeutics for the treatment of infection with blood-borne pathogens of current global interest, specifically viral hepatitis and HIV/AIDS. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HBV, HCV, and HIV infection. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.

Table of Contents

Strategic Analysis of Antiviral Drug Development for Viral Hepatitis and HIV/AIDS Analysis of the Hepatitis/HIV Antiviral MarketExecutive SummaryMethodology and ScopeIntroductionHBV Antiviral MarketHCV Antiviral MarketHIV Antiretroviral MarketConclusions and RecommendationsAppendixThe Frost & Sullivan Story




Keyword1

Keyword2

Keyword3

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.